Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2011. The report details a specific share repurchase transaction executed on August 3, 2011, authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,700,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,355.5 pence per share; lowest price paid was 1,312 pence per share.
- Treasury Holdings (Settled): 497,521,816 shares (8.88% of total issued share capital).
- Treasury Holdings (Including Unsettled): 501,296,816 shares (9.81% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,107,661,073 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1.7 million shares. Consequently, the percentage of shares held in Treasury increased to 8.88% of issued capital and 9.81% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intention is to hold the repurchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (5,107,661,073) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the current percentage of voting rights held in Treasury (9.81% including unsettled shares).
- Review the price range paid (1,312 to 1,355.5 pence) against market prices on August 3, 2011.